[Research progress on development and utilization of minor ginsenosides].

Minor ginsenosides are a class of processed saponins with minor natural content, high bioavailability, and outstanding bio-logical activity, which are usually obtained by biological or chemical transformation of prototype saponins directly extracted from Panax plants. In recent years, with the clarification of the biosynthetic pathway of saponins and the development of synthetic biology, it has become possible to use synthetic metabolic engineering methods with microorganisms as hosts to produce saponins. Minor ginsenosides have received widespread attention because of their remarkable biological activities in enhancing the immune function of the body and antitumor property. At present, most of the reviews on minor ginsenosides focus on transformation preparation, process optimization, and pharmacological activity, but there are some deficiencies in industrial analysis. This study summarized structural types, pharmacological activities, sources of acquisition, and transformation pathways of minor ginsenosides based on the relevant literature in China and abroad, proposed problems in the preparation of existing minor ginsenosides, and discussed the future research and utilization prospects, to provide a theoretical basis for improving the basic research of minor ginsenosides and promoting their industrialization.

A chronological model for the Late Paleolithic at Shuidonggou Locality 2, North China.

The site of Shuidonggou Locality 2 offers important evidence for the Late Paleolithic sequence of north China. The site not only contains one of the earliest instances of ornamental freshwater shell and ostrich eggshell beads in the region, but also stone artifacts with features arguably resembling the Initial Upper Paleolithic (IUP) blade technology found farther north. The appearance of these innovative archaeological forms have been attributed to the arrival of hominin populations, possibly modern humans, into the region during Marine Isotope Stage 3. Yet, the chronology of the site remains debated due to ambiguities in the existing dates. In this study, we conduct a systematical radiocarbon analysis of charcoal and ostrich eggshell samples obtained throughout the site sequence. Both acid-base-acid and the more stringent acid-base-oxidation pretreatment methods were applied to the charcoal samples. The resulting ages follow an age-depth relationship that is consistent with the stratigraphic profile. In line with previous stratigraphic assessments, Bayesian age modeling suggests that site formation history can be split into two phases: an early phase 43-35 cal kBP associated with a lacustrine depositional environment, and a later phase 35-28 cal kBP associated with rapid terrestrial silt accumulation. The chronology of the archaeological layers containing IUP-like artifacts are placed at 43-39 cal kBP and 35-34 cal kBP respectively. This finding supports the interpretation that an IUP-like blade technology appeared in the SDG region by at least ~41 ka.

CXCL13 blockade attenuates lupus nephritis of MRL/lpr mice.

The chemokine CXC ligand 13 protein (CXCL13) is reported to closely related to the disease activity and severity of systemic lupus erythematosus (SLE), moreover, the level of CXCL13 was markedly raised in kidney tissues of lupus nephritis (LN) patients. The aim of the present study was to explore whether the blockade of CXCL13 has therapeutic effects on murine LN. MRL/lpr mice received 50µg anti-CXCL13 neutralizing antibody or isotype IgG by intraperitoneal injection everyday for six weeks, and renal damage of each group was determined. Our results showed that the blockade of CXCL13 significantly reduced urine protein, serum creatinine, and dramatically attenuated renal pathology injury. Treatment with anti-CXCL13Ab also reduced serum anti-dsDNA level, renal immune complex deposition as well as inflammatory cytokines secretion. Meanwhile, Th17/Treg ratio in spleens of MRL/lpr mice was significantly decreased by the blocking of CXCL13. These findings suggested that CXCL13 may be a promising target for the therapy of LN.